Efficacy of Mesenchymal Stem Cells in Treating Peritoneal Fibrosis in Animal Models
Author Information
Author(s): L. Zheng, Chen Wenmin, Yao Kaijin, Xie Yina, Liao Chunling, Lin Yongda, Zhou Tianbiao
Primary Institution: Department of Nephrology, the Second Affiliated Hospital of Shantou University Medical College, Shantou, China
Hypothesis
This meta-analysis evaluates the efficacy of mesenchymal stem cells (MSCs) therapy in animal models of peritoneal fibrosis.
Conclusion
MSC therapy significantly improves peritoneal function and reduces fibrotic and inflammatory responses in animal models.
Supporting Evidence
- MSC therapy significantly reduced inflammatory cytokines like IL-6 and TGF-β.
- MSC treatment improved ultrafiltration capacity in animal models.
- MSC therapy decreased submesothelial thickness in peritoneal fibrosis models.
- MSC treatment showed no significant differences in VEGF levels compared to controls.
Takeaway
Scientists studied how special cells called mesenchymal stem cells can help fix problems in the belly caused by dialysis. They found that these cells can make things better.
Methodology
A systematic review and meta-analysis of 15 studies evaluating MSC therapy in animal models of peritoneal fibrosis.
Potential Biases
High risk of bias due to lack of blinding in many studies.
Limitations
The study's conclusions are limited by the quality and quantity of included articles, and the results need validation through clinical trials.
Participant Demographics
Animal models included Wistar albino rats, Sprague-Dawley rats, and C57BL/6 mice.
Statistical Information
P-Value
p<0.00001
Confidence Interval
95% CI: −2.32, −1.25
Statistical Significance
p<0.00001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website